Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 4, 2008, Pages 1591-1598

  Saito, Yuta ^a   Uppal, Abhineet ^b   Byfield, Grace ^b   Budd, Steven ^b   Hartnett, M Elizabeth ^b  

^a SHOWA UNIVERSITY   (Japan)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOCYNIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; OXYGEN; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASCULOTROPIN; ENZYME INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; NONHUMAN; OXYGENATION; PREMATURITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RETINA CELL; RETINOPATHY; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; HYPEROXIA; IMMUNOPRECIPITATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHOSPHORYLATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYPEROXIA; IMMUNOPRECIPITATION; INFANT, NEWBORN; INJECTIONS, INTRAPERITONEAL; JANUS KINASES; NADPH OXIDASE; OXIDATIVE STRESS; OXYGEN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45549090431     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1356     Document Type: Article

References (65)

1. Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retro- lental fibroplasia. Br J Ophthalmol. 1954;38:397-430.
2. Patz A, Eastham A, Higginbotham DH, Kleh T. Oxygen studies in retrolental fibroplasia. Am J Ophthalmol. 1953;36:1511-1522.
3. Gao G, Li Y, Zhang D, et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001;489:270-276.
4. Chan-Ling T, Gock B, Stone J. Supplemental oxygen therapy: basis for noninvasive treatment of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1995;36:1215-1230.
5. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
6. Ernest JT, Goldstick TK. Retinal oxygen tension and oxygen reactivity in retinopathy of prematurity in kittens. Invest Ophthalmol Vis Sci. 1984;25:1129-1134.
7. Dorey CK, Aouididi S, Reynaud X, Dvorak HF, Brown LF. Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Oph- thalmol. 1996;114:1210-1217.
8. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularisation in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34:576-585.
9. McLeod DS, Crone SN, Lutty GA. Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 1996;37:1322-1333.
10. Phelps DL. Reduced severity of oxygen-induced retinopathy in kittens recovered in 28% oxygen. Pediatr Res. 1988;24:106-109.
11. Gu X, Samuel S, El Shabrawey M, et al. Effects of sustained hyper- oxia on revascularization in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2002;43:496-502.
12. Berkowitz BA, Zhang W. Significant reduction of the panretinal oxygenation response after 28% supplemental oxygen recovery in experimental ROP. Invest Ophthalmol Vis Sci. 2000;41:1925-1931.
13. The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP- ROP), a randomized, controlled trial, I: primary outcomes. Pediatrics. 2000;105:295-310.
14. McColm JR, Cunningham S, Wade J, et al. Hypoxic oxygen fluctuations produce less severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of prematurity. Pediatr Res. 2004; 55:107-113.
15. Cunningham S, Fleck BW, Elton RA, McIntosh N. Transcutaneous oxygen levels in retinopathy of prematurity. Lancet. 1995;346: 1464-1465.
16. Saito Y, Omoto T, Cho Y, et al. The progression of retinopathy of prematurity and fluctuation in blood gas tension. Graefes Arch Clin Exp Ophthalmol. 1993;231:151-156.
17. Chow LC, Wright KW, Sola A. Can changes in clinical practice ecrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics. 2003;111:339-345.
18. Tin W, Milligan DWA, Pennefather PM, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonat Ed. 2001;84: 106-110.
19. Flynn JT. Retinopathy of prematurity. Ped Clin N Am. 1987;34: 1487-1516.
20. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 51/2 years in premature infants with birth weights less than 1251g. Arch Ophthalmol. 2002;120:595-599.
21. Michaelson IC. The mode of development of the vascular system of the retina: with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK. 1948;68:137.
22. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18: 1450-1452.
23. Ishida S, Yamashiro K, Usui T, et al. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003;9:781-789.
24. -/- mice. Dev Biol. 2005;279:205-219.
25. Shih SC, Ju M, Liu N, Smith LEH. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinop- athy of prematurity. J Clin Invest. 2003;112:50-57.
26. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1: 1024-1028.
27. Chang KH, Chan-Ling T, McFarland EL, et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA. 2007;104:10595-10600.
28. Lofqvist C, Chen J, Connor KM, et al. From the cover: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA. 2007;104:10589-10594.
29. Neu J, Afzal A, Pan H, et al. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2006;47:3151-3155.
30. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of [omega]-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13:868- 873.
31. Saito Y, Geisen P, Uppal A, Hartnett ME. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis. 2007;13:840-853.
32. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med. 2007;42:153-164.
33. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res. 2006;71:226-235.
34. Parinandi NL, Kleinberg MA, Usatyuk PV, et al. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am JPhysiol Lung Cell Mol Physiol. 2003;284:L26-L38.
35. Penn JS. Oxygen-induced retinopathy in the rat: vitamins C and E as potential therapies. Invest Ophthalmol Vis Sci. 1992;33:1836-1845.
36. Niesman MR, Johnson KA, Penn JS. Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity. Neurochem Res. 1997;22:597- 605.
37. Penn JS, Tolman BL, Bullard LE. Effect of a water-soluble vitamin E analog, Trolox C, on retinal vascular development in an animal model of retinopathy of prematurity. Free Radic Biol Med. 1997;22:977-984.
38. Jay Forman H, Torres M. Redox signaling in macrophages. Mol Aspects Med. 2001;22:189-216.
39. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. AJP Regul Integrative Comp Physiol. 2004;287:R1014-R1030.
40. Holmes JM, Duffner LA. The effect of postnatal growth retardation on abnormal neovascularization in the oxygen exposed neonatal rat. Curr Eye Res. 1996;15:403- 409.
41. Hartnett ME, Martiniuk DJ, Saito Y, et al. Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphor- ylation in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2006;47:4975- 4982.
42. Penn JS, McCollum GW, Barnett JM, et al. Angiostatic effect of penetrating ocular injury: role of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2006;47:405- 414.
43. Hart BA, Simons JM. Metabolic activation of phenols by stimulated neutrophils: a concept for a selective type of anti-inflammatory drug. Bio Technol Therapeutics. 1992;3:119-135.
44. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol. 1994;11:95-102.
45. Al Shabrawey M, Bartoli M, El Remessy AB, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol. 2005;167:599-607.
46. Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper BK, Drum- mond GR. Nitric oxide suppresses NADPH oxidase- dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res. 2007;75:349-358.
47. Piccoli C, D'Aprile A, Ripoli M, et al. Bone-marrow derived hematopoietic stem/progenitor cells express multiple isoforms of NADPH oxidase and produce constitutively reactive oxygen species. Biochem Biophys Res Comm. 2007;353:965-972.
48. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem. 2005;V264:85-97.
49. Barbieri SS, Eligini S, Brambilla M, Tremoli E, Colli S. Reactive oxygen species mediate cyclooxygenase-2 induction during mono- cyte to macrophage differentiation: critical role of NADPH oxi- dase. Cardiovasc Res. 2003;60:187-197.
50. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245-313.
51. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000;87:179-183.
52. Arteel GE, Thurman RG, Yates JM, Raleigh JA. Evidence that hyp- oxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br JCancer. 1995;72:889-895.
53. Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem. 1998;253:743-750.
54. Rijken PFJW, Bernsen HJJA, Peters JPW, et al. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Physics. 2000;48:571-582.
55. Kennedy AS, Raleigh JA, Perez GM, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Physics. 1997;37:897-905.
56. Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 1999;151:580-589.
57. Werdich XQ, Penn JS. Specific involvement of Src family kinase activation in the pathogenesis of retinal neovascularization. Invest Ophthalmol Vis Sci. 2006;47:5047-5056.
58. Geisen P, Peterson L, Martiniuk D, et al. Neutralizing antibody to VEGF reduces intravitreous neovascularization and does not interfere with vascularization of avascular retina in an ROP model. Mol Vis. 2008;14:345-357.
59. Armstrong D, Ueda T, Ueda T, et al. Expression of TNF- alpha and VEGF during retinal neovascularization is initiated by lipid hydroperoxide. Angiogenesis. 1997;1:174-184.
60. Armstrong D, Ueda T, Aljeda A, et al. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of TNF-alpha, VEGF, and PDGF. Angiogenesis. 1998;2:93-104.
61. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
62. Akula JD, Hansen RM, Martinez-Perez ME, Fulton AB. Rod photo- receptor function predicts blood vessel abnormality in retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2007;48:4351-4359.
63. Berkowitz BA, Roberts R, Penn JS, Gradianu M. High-resolution manganese-enhanced MRI of experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2007;48:4733-4740.
64. Cringle SJ, Yu PK, Su EN, Yu DY. Oxygen distribution and consumption in the developing rat retina. Invest Ophthalmol Vis Sci. 2006;47:4072-4076.
65. Jankov RP, Negus A, Tanswell AK. Antioxidants as therapy in the newborn: some words ofcaution. Pediatr Res. 2001;50:681-687.